Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.

Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, Rofiq A, Prijanto M, Julitasari, Yela U, Herzog C, Cryz SJ.

Vaccine. 2006 Mar 10;24(11):1776-85. Epub 2005 Oct 27.

PMID:
16303216
2.
3.

Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates.

Rubinstein A, Mizrachi Y, Pettoello-Mantovani M, Lenz J, Liu GQ, Rubinstein Y, Goldstein H, Yust I, Burke M, Vardinon N, Spirer Z, Cryz SJ Jr.

J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):467-76.

PMID:
10961608
4.
5.

Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.

Panpitpat C, Thisyakorn U, Chotpitayasunondh T, Fürer E, Que JU, Hasler T, Cryz SJ Jr.

Bull World Health Organ. 2000;78(3):364-71.

6.

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.

Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O'Hanley PP, Cryz SJ, Simanjuntak CH.

Vaccine. 2000 May 8;18(22):2399-410.

PMID:
10738097
7.
8.

Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity.

Dilts DA, Riesenfeld-Orn I, Fulginiti JP, Ekwall E, Granert C, Nonenmacher J, Brey RN, Cryz SJ, Karlsson K, Bergman K, Thompson T, Hu B, Brückner AH, Lindberg AA.

Vaccine. 2000 Feb 14;18(15):1473-84.

PMID:
10618545
9.
10.

Immunotherapy of sepsis: flawed concept or faulty implementation?

Cross AS, Opal SM, Bhattacharjee AK, Donta ST, Peduzzi PN, Fürer E, Que JU, Cryz SJ.

Vaccine. 1999 Oct 1;17 Suppl 2:S13-21. Review.

PMID:
10506404
11.

BERNA: a century of immunobiological innovation.

Cryz SJ.

Vaccine. 1999 Oct 1;17 Suppl 2:S1-5.

PMID:
10506402
12.
13.

Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.

Richie E, Punjabi NH, Harjanto SJ, Wangsasaputral F, Sukandar M, Supriatman M, Simanjuntak CH, Que JU, Cryz SJ Jr.

Vaccine. 1999 Mar 17;17(11-12):1384-93.

PMID:
10195774
14.

Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA, Wasserman SS, Levine MM, Cryz SJ.

Infect Immun. 1999 Apr;67(4):2030-4.

15.

Compatible concurrent administration of yellow fever 17D vaccine with oral, live, attenuated p6olera CVD103-HgR and typhoid ty21a vaccines.

Tsai TF, Kollaritsch H, Que JU, Cropp CB, Kunz C, Wiedermann G, Herzog C, Cryz SJ.

J Infect Dis. 1999 Feb;179(2):522-4. No abstract available.

PMID:
9878043
16.
17.

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.

Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, Tischer A, Gassner M, Glück R, Stück B, Cryz SJ Jr.

Vaccine. 1998 Jan-Feb;16(2-3):298-304.

PMID:
9607046
18.

Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis.

Fryauff DJ, Cryz SJ, Widjaja H, Mouzin E, Church LW, Sutamihardja MA, Richards AL, Subianto B, Hoffman SL.

J Infect Dis. 1998 Jun;177(6):1762-5.

PMID:
9607867
19.
20.

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients.

Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, Glück R, Cryz SJ Jr.

Vaccine. 1997 Oct;15(15):1675-9.

PMID:
9364699
21.

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R, Levine MM, Cryz SJ.

Infect Immun. 1997 Sep;65(9):3852-6.

22.

Live oral cholera vaccine.

Herzog C, Wegmüller B, Cryz SJ.

Lancet. 1997 Jun 14;349(9067):1772-3. No abstract available.

PMID:
9193404
23.
24.

Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.

Chotpitayasunondh T, Panpitpat C, Thisyakorn U, Furer E, Que JU, Hasler T, Cryz SJ Jr.

Southeast Asian J Trop Med Public Health. 1997 Mar;28(1):91-8.

PMID:
9322290
25.

Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Cryz SJ Jr, Lang A, Rüdeberg A, Wedgwood J, Que JU, Fürer E, Schaad U.

Behring Inst Mitt. 1997 Feb;(98):345-9.

PMID:
9382759
26.

Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.

Johansen HK, Cryz SJ Jr, Hougen HP, Moser C, Høiby N.

Behring Inst Mitt. 1997 Feb;(98):269-73. Review.

PMID:
9382750
27.
28.

Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults.

Briggs DJ, Dreesen DW, Morgan P, Chin JE, Seedle CD, Cryz L, Glück R, Cryz SJ.

Vaccine. 1996 Oct;14(14):1361-5.

PMID:
9004446
29.

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group.

Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ Jr, Kauffman C, Bradley S, Gafford G, Elliston D, Beam TR Jr, John JF Jr, Ribner B, Cantey R, Welsh CH, Ellison RT 3rd, Young EJ, Hamill RJ, Leaf H, Schein RM, Mulligan M, Johnson C, Abrutyn E, Griffiss JM, Slagle D, et al.

J Infect Dis. 1996 Sep;174(3):537-43.

PMID:
8769611
30.
31.

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.

Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JD Jr, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC.

Vaccine. 1996 Jun;14(8):817-27.

PMID:
8817830
32.

Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR.

Favre D, Struck MM, Cryz SJ Jr, Viret JF.

Vaccine. 1996 Apr;14(6):526-31.

PMID:
8782351
33.
34.

Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae.

Viret JF, Cryz SJ Jr, Favre D.

Mol Microbiol. 1996 Mar;19(5):949-63.

PMID:
8830276
36.

Factors influencing the stability of live oral attenuated bacterial vaccines.

Cryz SJ Jr, Pasteris O, Varallyay SJ, Fürer E.

Dev Biol Stand. 1996;87:277-81.

PMID:
8854028
37.
38.

Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats.

Johansen HK, Hougen HP, Cryz SJ Jr, Rygaard J, Høiby N.

Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1337-46.

PMID:
7551392
39.

Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais.

Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Glück R, Cryz SJ Jr.

Vaccine. 1995 Jul;13(10):891-3.

PMID:
7483760
40.
41.

Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.

Cryz SJ Jr, Que JO, Cross AS, Fürer E.

Vaccine. 1995 Apr;13(5):449-53.

PMID:
7639013
42.

Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients.

Wilde H, Glueck R, Khawplod P, Cryz SJ, Tantawichien T, Thipkong P, Chomchey P, Prakongsri S, Benjavongkulchai M, Sumboonanondha A, et al.

Vaccine. 1995 Apr;13(6):593-6.

PMID:
7483780
43.

Anti-hepatitis A antibody titers after passive immunization with hepatitis A hyperimmune globulin.

Poovorawan Y, Theamboonlers A, Vimolkej L, Cryz SJ Jr.

Southeast Asian J Trop Med Public Health. 1995 Mar;26(1):193-4. No abstract available.

PMID:
8525412
44.

Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.

Rubinstein A, Goldstein H, Pettoello-Mantovani M, Mizrachi Y, Bloom BR, Furer E, Althaus B, Que JU, Hasler T, Cryz SJ.

AIDS. 1995 Mar;9(3):243-51.

PMID:
7755912
45.

Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.

Cryz SJ Jr, Kaper J, Tacket C, Nataro J, Levine MM.

Dev Biol Stand. 1995;84:237-44. Review.

PMID:
7796960
46.

Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine.

Cryz SJ Jr, Goldstein H, Pettoello-Mantovani M, Kim A, Fürer E, Que JU, Hasler T, Rubinstein A.

Vaccine. 1995 Jan;13(1):67-71.

PMID:
7762281
47.

Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O.

Tacket CO, Losonsky G, Nataro JP, Wasserman SS, Cryz SJ, Edelman R, Levine MM.

Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):75-7.

PMID:
7747315
48.

Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.

Edelman R, Taylor DN, Wasserman SS, McClain JB, Cross AS, Sadoff JC, Que JU, Cryz SJ.

Vaccine. 1994 Nov;12(14):1288-94.

PMID:
7856293
49.

Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers.

Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ Jr.

J Infect Dis. 1994 Oct;170(4):834-40.

PMID:
7523536
50.

Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Johansen HK, Espersen F, Cryz SJ Jr, Hougen HP, Fomsgaard A, Rygaard J, Høiby N.

Infect Immun. 1994 Aug;62(8):3146-55.

Supplemental Content

Support Center